Skip to main content
. 2015 Oct 8;10(10):e0140189. doi: 10.1371/journal.pone.0140189

Fig 3. IGF-I enhanced p53-p21 pathway in human fibroblasts.

Fig 3

A, B, p53 and p21 mRNA expression in human fibroblasts treated with GH or IGF-I for 27 days (PDL of 20–21). The expressions were measured using quantitative RT-PCR and normalized to β-actin. C, Immunoblotting analysis of p53, serine-phosphorylated-p53 (p-p53), and p21 proteins in human fibroblasts treated with GH or IGF-I for 27 days (PDL of 20–21). Anti-p-p53 protein at serine 15 antibody was used for the detection of p-p53. D, E, Densitometric analysis of p53, p-p53, and p21 protein levels normalized to β-actin. All data are expressed as mean ± standard deviation. Data were compared using one-way analysis of variance followed by post hoc Fisher’s least significant difference test. *P < 0.05, **P < 0.01; PDL, population doubling levels.